Funding for this research was provided by:
Universitätsklinikum Erlangen
Article History
Accepted: 19 May 2024
First Online: 22 June 2024
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. The study was supported by the Matthias-Lackas-Stiftung and the Hiege Foundation (die Deutsche Hautkrebsstiftung). MVH was supported by an Else-Kröner Fresenius Excellence Fellowship. EATK was supported by the Clinician Scientist Programme of the IZKF (Interdisciplinary Center for Clinical Research) at the Medical Faculty of the FAU Erlangen. EATK and MVH were supported by the clinician-scientist program awarded by the German Society of Dermatology (DDG) and the Arbeitsgemeinschaft Dermatologische Forschung (ADF).
: CB has received honoraria for consultancy and/or speaker´s fees from BMS, Almirall, InflaRx, Leo Pharma, Novartis, MSD, Pierre Fabre, Immunocore, Delcath, Sanofi, and Regeneron. EATK declares no conflicts of interest that might be relevant to the contents of this article. MVH received honoraria from MSD, BMS, Roche, Novartis, Sun Pharma, Sanofi, Almirall, Immunocore, Biofrontera, Galderma, and Pierre Fabre.
: Not applicable.
: Not applicable.
: Not applicable.
: No datasets were generated or analyzed during the current study.
: Not applicable.
: EATK wrote the draft of the manuscript. CB and MVH revised and edited the manuscript.